IL6 and congenital rubella syndrome: In cancer patients, CRS and immune effector cell-associated neurotoxicity syndrome (ICANS) are major safety concerns, both arising from excessive cytokine release (e.g., IFN-γ, IL-6) by activated CAR-T cells.